Custirsen

Last updated
Custirsen
Custirsen.svg
Clinical data
Other namesOGX-011, CC-8490
Identifiers
CAS Number
DrugBank
ChemSpider
UNII
Chemical and physical data
Formula C231H312N78O119P20S20

Custirsen, with aliases including custirsen sodium, OGX-011, and CC-8490, is an investigational drug that is under clinical testing for the treatment of cancer. It is an antisense oligonucleotide (ASO) targeting clusterin expression. [1] In metastatic prostate cancer, custirsen showed no benefit in improving overall survival. [2] [3]

Contents

Custirsen was developed through a collaboration between OncoGenex Pharmaceuticals Inc. and Isis. In 2009, OncoGenex Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. agreed to develop and commercialise Custirsen.

Mechanism of action

An antisense oligonucleotide (ASO) is a single-strand DNA sequence complementary to a desired messenger RNA (mRNA) sequence. Antisense therapy targets gene sequences using antisense oligonucleotides by binding the ASO to the mRNA strand. This creates an inhibitory complex that reduces plasma protein levels by preventing translation. [4]

Custirsen is a second-generation phosphorothioate antisense oligonucleotide. Phosphorothioates are oligonucleotides with a sulfur ion replacing an oxygen molecule in the chain. They have high antisense activity due to their increased chirality, nuclease stability, and solubility. [5] Second-generation oligonucleotides are highly specific to the target mRNA sequence, increasing the affinity of the compound. Custirsen acts as an anti-cancer drug by binding to the mRNA initiation site of the clusterin gene, reducing clusterin protein plasma concentrations. The synthetic addition of a 2’-methoxyethyl on each nucleotide bookending the phosphorothioate backbone causes: [4]

Clusterin is upregulation in many tumours including prostate, breast, non-small cell lung, ovary and colorectal. It has been linked with the development of aggressive tumours by protecting the cells from apoptosis. [4] It is also upregulated in response to standard cancer treatments including chemotherapy, androgen deprivation therapy, and radiation therapy. This resistance is caused by the inhibition of the pro-apoptotic BLC2 gene, prevention of protein aggregation, and increased NF-KB. [6]

The anti-apoptotic activity of clusterin in aiding tumour growth is due to interactions with protein complexes. These include: [4]

Pharmacokinetics

A meta-analysis study evaluated 5588 Custirsen plasma concentrations from 631 subjects over seven clinical studies. Subjects with cancer received multiple doses between 40 mg and 640 mg intravenously over two hours, whilst healthy subjects received either a single or double dose at 320 mg-640 mg. [7]

Three compartment model Schematic-representation-of-a-three-compartment-model.png.jpg
Three compartment model

The pharmacokinetics of Custirsen was described by a three-compartment model with first-order elimination where:

For a representative sixty-six year old with a body mass (kg) of eighty-two and a blood Custirsen level of 0.933 mg/dL, the estimated parameter values were: [7]

Side effects

CT scan of prostate cancer CT of prostate cancer.jpg
CT scan of prostate cancer

A phase I study investigated the maximum tolerated dose of Custirsen in patients with recurrent or refractory high-grade gliomas. [8]

The recommended and safe dosing of Custirsen was determined in a Phase I same-dose escalation scheme involving forty patients with tumours known to upregulate clusterin with metastatic or locally recurrent disease (prostate, ovary, breast). Custirsen was infused intravenously on days 1, 3, and 5, with weekly dosing starting on day 8 for four weeks. The drug was increasingly administered in six dose cohorts of 40 mg, 80 mg, 160 mg, 320 mg, 480 mg, and 640 mg. [8]

The results found that the recommended dose of Custirsen was 640 mg, with maximum decrease of clusterin blood plasma occurring at this dose. Researchers found a statistically significant increase in the apoptotic index in prostatectomy specimens. [8]

This study provided the dosing framework for further studies into Custirsen, determining 640 mg as a tolerable and biologically active dose. [8]

In this study, no dose-limiting toxicities were reported in doses up to and including 480 mg. For patients who received the 640 mg dose, the following adverse reactions were present: [4]

Pleural effusion of the left lung Left-sided Pleural Effusion.jpg
Pleural effusion of the left lung

In patients who received combined treatment with Docetaxel, four of sixteen patients experienced dose-limiting toxicities at 640 mg: [4]

Phase III Studies

Phase III studies into the effectiveness of the combinational treatment of Custirsen and chemotherapy as a treatment of metastatic-castration-resistant prostate cancer and also Custirsen as a biomarker for clusterin are currently under evaluation.

The Phase III SYNERGY trial looked into the addition of Custirsen to first-line Docetaxel and Prednisone chemotherapy, concluding that there was no marked increased survival rate compared to the Custirsen-independent treatment group. Researchers also found no difference in the progressive rates of the cancer. Contrasting previous research, subjects in the Custirsen group had more adverse reactions to the treatment than the Custirsen-independent group. [4]

The findings of this clinical study contradict the results found in previous studies. However, researchers suggested further studies into patients with metastatic-castration-resistant prostate cancer whom have poor prognostic features, believing there is a therapeutic effect of Custirsen in individuals with this feature of the disease. [9]

Related Research Articles

Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockage, and exon content modulation through splicing site binding on pre-mRNA. Several ASOs have been approved in the United States, the European Union, and elsewhere.

<span class="mw-page-title-main">Bicalutamide</span> Prostate cancer treatment

Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC). To a lesser extent, it is used at high doses for locally advanced prostate cancer (LAPC) as a monotherapy without castration. Bicalutamide was also previously used as monotherapy to treat localized prostate cancer (LPC), but authorization for this use was withdrawn following unfavorable trial findings. Besides prostate cancer, bicalutamide is limitedly used in the treatment of excessive hair growth and scalp hair loss in women, as a puberty blocker and component of feminizing hormone therapy for transgender girls and women, to treat gonadotropin-independent early puberty in boys, and to prevent overly long-lasting erections in men. It is taken by mouth.

<span class="mw-page-title-main">Docetaxel</span> Chemotherapy medication

Docetaxel, sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. It may be used by itself or along with other chemotherapy medication. It is given by slow injection into a vein.

Nicholas J. Vogelzang was a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as medical director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.

<span class="mw-page-title-main">Satraplatin</span> Chemical compound

Satraplatin is a platinum-based antineoplastic agent that was under investigation as a treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum-based chemotherapeutic drug; other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.

<span class="mw-page-title-main">Atrasentan</span> Chemical compound

Atrasentan is an experimental drug that is being studied for the treatment of various types of cancer, including non-small cell lung cancer. It is also being investigated as a therapy for diabetic kidney disease.

<span class="mw-page-title-main">Enzalutamide</span> Antiandrogen medication used in treatment of prostate cancer

Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), nonmetastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer (mCSPC). It is taken by mouth.

James L. Gulley is an American cancer researcher and the Director of the Medical Oncology Service at National Cancer Institute.

<span class="mw-page-title-main">Genta (company)</span> Biotechnology company

Genta Incorporated was a biopharmaceutical company started in La Jolla, California, which discovered and developed innovative drugs for the treatment of patients with cancer. Founded in 1989 by a highly skilled entrepreneur, the company focused on a novel technology known as antisense, which targets gene products that are associated with the onset and progression of serious diseases. At that time, only Ionis Pharmaceuticals, Inc. was conducting significant research with this technology. Antisense is a short span of oligonucleotides – modified DNA structures ranging from about 12-24 bases that selectively bind to specific RNA. The intent is to block expression of an aberrant protein that contributes to the disease of interest. Genta in-licensed three different antisense molecules that blocked Bcl-2, a fibroblast growth factor (FGF), and the gene c-myb, respectively.

<span class="mw-page-title-main">Cabazitaxel</span> Chemical compound

Cabazitaxel, sold under the brand name Jevtana, is a semi-synthetic derivative of a natural taxoid. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.

<span class="mw-page-title-main">Zibotentan</span> Chemical compound

Zibotentan is an experimental anti-cancer drug candidate in development by AstraZeneca. It is an endothelin receptor antagonist.

Gataparsen is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.

Demcizumab is a humanized monoclonal antibody which is used to treat patients with pancreatic cancer or non-small cell lung cancer. Demcizumab has completed phase 1 trials and is currently undergoing phase 2 trials. Demcizumab was developed by OncoMed Pharmaceuticals in collaboration with Celgene.

PROSTVAC is a cancer immunotherapy candidate in clinical development by Bavarian Nordic for the treatment of all prostate cancer although clinical trials are focusing on more advanced cases of metastatic castration-resistant prostate cancer (mCRPC). PROSTVAC is a vaccine designed to enable the immune system to recognize and attack prostate cancer cells by triggering a specific and targeted T cell immune response to cancer cells that express the tumor-associated antigen prostate-specific antigen (PSA).

Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. The medication is taken by mouth twice per day with food.

<span class="mw-page-title-main">Apalutamide</span> Chemical compound

Apalutamide, sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is specifically indicated for use in conjunction with castration in the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC). It is taken by mouth.

<span class="mw-page-title-main">Vosilasarm</span> Chemical compound

Vosilasarm, also known by the development codes RAD140 and EP0062 and by the black-market name Testolone or Testalone, is a selective androgen receptor modulator (SARM) which is under development for the treatment of hormone-sensitive breast cancer. It is specifically under development for the treatment of androgen receptor-positive, estrogen receptor-negative, HER2-negative advanced breast cancer. Vosilasarm was also previously under development for the treatment of sarcopenia, osteoporosis, and weight loss due to cancer cachexia, but development for these indications was discontinued. The drug is taken by mouth.

Viralytics Ltd is an Australian biotechnology company working in the field of oncolytic viruses, that is, viruses that preferentially infect and kill cancer cells. The company's oncolytic virus product, called Cavatak, is currently in clinical trials in metastatic melanoma and other cancers. The drug was granted Orphan Drug status in advanced melanoma in December 2005.

Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer.

<span class="mw-page-title-main">Ralaniten acetate</span> Chemical compound

Ralaniten acetate is a first-in-class antiandrogen that targets the N-terminal domain (NTD) of the androgen receptor (AR) developed by ESSA Pharmaceuticals and was under investigation for the treatment of prostate cancer. This mechanism of action is believed to allow the drug to block signaling from the AR and its splice variants. EPI-506 is a derivative of bisphenol A and a prodrug of ralaniten (EPI-002), one of the four stereoisomers of EPI-001, and was developed as a successor of EPI-001. The drug reached phase I/II prior to the discontinuation of its development. It showed signs of efficacy in the form of prostatic specific antigen (PSA) decreases (4–29%) predominantly at higher doses (≥1,280 mg) in some patients but also caused side effects and was discontinued by its developer in favor of next-generation AR NTD inhibitors with improved potency and tolerability.

References

  1. ↑ Chi KN, Zoubeidi A, Gleave ME (December 2008). "Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer". Expert Opinion on Investigational Drugs. 17 (12): 1955–62. doi:10.1517/13543780802528609. PMID   19012510. S2CID   72504146.
  2. ↑ Sidaway P (June 2017). "Prostate cancer: Custirsen fails to improve outcomes". Nature Reviews. Urology. 14 (6): 327. doi:10.1038/nrurol.2017.51. PMID   28352135. S2CID   20465674.
  3. ↑ Zhang X, Liu C, Li K, Wang K, Zhang Q, Cui Y (February 2019). "Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer". Medicine. 98 (6): e14254. doi:10.1097/MD.0000000000014254. PMC   6380863 . PMID   30732140.
  4. 1 2 3 4 5 6 7 Higano CS (2013-06-25). "Potential use of custirsen to treat prostate cancer". OncoTargets and Therapy. 6: 785–97. doi: 10.2147/OTT.S33077 . PMC   3699352 . PMID   23836992.
  5. ↑ Dias N, Stein CA (March 2002). "Antisense oligonucleotides: basic concepts and mechanisms". Molecular Cancer Therapeutics. 1 (5): 347–55. PMID   12489851.
  6. ↑ Clinical trial number NCT01630733 for "A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer" at ClinicalTrials.gov
  7. 1 2 Edwards AY, Elgart A, Farrell C, Barnett-Griness O, Rabinovich-Guilatt L, Spiegelstein O (September 2017). "A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects". British Journal of Clinical Pharmacology. 83 (9): 1932–1943. doi:10.1111/bcp.13287. PMC   5555861 . PMID   28294391.
  8. 1 2 3 4 "A Phase I Trial Of CC-8490 For The Treatment Of Patients With Recurrent/Refractory High-Grade Gliomas - ICH GCP - Clinical Trials Registry". ichgcp.net. Retrieved 2019-05-07.
  9. ↑ Chi KN, Higano CS, Blumenstein B, Ferrero JM, Reeves J, Feyerabend S, et al. (April 2017). "Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial". The Lancet. Oncology. 18 (4): 473–485. doi:10.1016/S1470-2045(17)30168-7. PMID   28283282.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.